175 related articles for article (PubMed ID: 34152396)
21. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
[TBL] [Abstract][Full Text] [Related]
22. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
23. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
Trudel S; Li ZH; Rauw J; Tiedemann RE; Wen XY; Stewart AK
Blood; 2007 Jun; 109(12):5430-8. PubMed ID: 17332241
[TBL] [Abstract][Full Text] [Related]
24. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
25. The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis.
Ren H; Koo J; Guan B; Yue P; Deng X; Chen M; Khuri FR; Sun SY
Mol Cancer; 2013 Nov; 12():146. PubMed ID: 24261825
[TBL] [Abstract][Full Text] [Related]
26. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
27. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
[TBL] [Abstract][Full Text] [Related]
28. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
He W; Fu Y; Zheng Y; Wang X; Liu B; Zeng J
BMC Cancer; 2021 Feb; 21(1):125. PubMed ID: 33549034
[TBL] [Abstract][Full Text] [Related]
29. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
30. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842
[TBL] [Abstract][Full Text] [Related]
31. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
Melvold K; Giliberto M; Karlsen L; Ayuda-Durán P; Hanes R; Holien T; Enserink J; Brown JR; Tjønnfjord GE; Taskén K; Skånland SS
Mol Oncol; 2022 Mar; 16(5):1153-1170. PubMed ID: 34861096
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
[TBL] [Abstract][Full Text] [Related]
33. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
34. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
35. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Leiba M; Jakubikova J; Klippel S; Mitsiades CS; Hideshima T; Tai YT; Leiba A; Pines M; Richardson PG; Nagler A; Anderson KC
Br J Haematol; 2012 Jun; 157(6):718-31. PubMed ID: 22533681
[TBL] [Abstract][Full Text] [Related]
36. Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2.
Basu A; Sridharan S
PLoS One; 2017; 12(3):e0173854. PubMed ID: 28301598
[TBL] [Abstract][Full Text] [Related]
37. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
38. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
39. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
[TBL] [Abstract][Full Text] [Related]
40. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.
Menoret E; Gomez-Bougie P; Geffroy-Luseau A; Daniels S; Moreau P; Le Gouill S; Harousseau JL; Bataille R; Amiot M; Pellat-Deceunynck C
Blood; 2006 Aug; 108(4):1346-52. PubMed ID: 16638930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
